Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 409 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Central Nervous System Viral Diseases Clear all
Enrolling by invitation Phase 1Phase 2 Interventional

rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease

NCT04833907
View directory record Official record
Conditions
Canavan Disease
Interventions
rAAV-Olig001-ASPA, Levetiracetam, Prednisone
Drug
Lead sponsor
Myrtelle Inc.
Industry
Eligibility
3 Months to 60 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 11, 2026, 5:53 PM EDT
Completed Early Phase 1 Interventional

NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy

NCT04781309
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy
Interventions
NT-I7
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 11, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

Stellate Ganglion Block for COVID-induced Parosmia

NCT06253806
View directory record Official record
Conditions
COVID-19-Induced Parosmia
Interventions
Stellate Ganglion Block, Placebo Sham Injection
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 11, 2026, 5:53 PM EDT
Completed No phase listed Observational

Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer

NCT00002485
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2005
U.S. locations
26
States / cities
Sacramento, California • Gainesville, Florida • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 11, 2026, 5:53 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT

NCT05327426
View directory record Official record
Conditions
Poliomyelitis
Interventions
Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT), Intradermal fractional dose inactivated polio vaccine (fIPV), Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain
Biological
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 11, 2026, 5:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Residential Care Transition Module

NCT02915939
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
The Residential Care Transition Module
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 11, 2026, 5:53 PM EDT
Completed Phase 2 Interventional

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

NCT00012467
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Itraconazole, Flucytosine, Fluconazole, Amphotericin B, Interferon gamma-1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Camden, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 11, 2026, 5:53 PM EDT
Completed Not applicable Interventional

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

NCT00002075
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 5:53 PM EDT
Completed Phase 1 Interventional

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

NCT00003368
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
45
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 11, 2026, 5:53 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)

NCT00459693
View directory record Official record
Conditions
HIV-Dementia, HIV-Associated Cognitive Motor Complex, AIDS Encephalopathy, AIDS Dementia Complex, AIDS-Related Dementia Complex, HIV Infections, Healthy
Interventions
[11C]PBR28
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 11, 2026, 5:53 PM EDT
Recruiting No phase listed Observational

Long-term Follow-up Study of Patients Receiving CAR-T Cells

NCT03375619
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Small Lymphocytic, Mantle Cell Lymphoma, Central Nervous System Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, Multiple Myeloma
Interventions
Long-Term Follow-Up of Participants who Received CAR-T cells
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 11, 2026, 5:53 PM EDT
Completed Not applicable Interventional

Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19

NCT04412330
View directory record Official record
Conditions
Covid-19, Critical Illness, Post Intensive Care Unit Syndrome, Muscle Weakness
Interventions
ICU Recovery + Physical Therapy
Other
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 11, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Results available

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

NCT00987948
View directory record Official record
Conditions
HIV Infections
Interventions
maraviroc (Selzentry)
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 11, 2026, 5:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease

NCT03454893
View directory record Official record
Conditions
Fabry Disease
Interventions
AVR-RD-01
Drug
Lead sponsor
AVROBIO
Industry
Eligibility
16 Years to 50 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Hackensack, New Jersey • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 11, 2026, 5:53 PM EDT
Terminated No phase listed Observational

C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study

NCT02568540
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 11, 2026, 5:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine

NCT02654509
View directory record Official record
Conditions
Eastern Equine Encephalitis
Interventions
Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 11, 2026, 5:53 PM EDT
Completed Phase 1 Interventional

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

NCT01231919
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Aggressive NK-cell Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myeloid/NK-cell Acute Leukemia, Noncutaneous Extranodal Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 11, 2026, 5:53 PM EDT
Completed Phase 3 Interventional

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

NCT00006348
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ondansetron, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 11, 2026, 5:53 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Longitudinal Innate Immunity and Aging Study

NCT03944603
View directory record Official record
Conditions
Healthy Older Adults Ages 60-89
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 11, 2026, 5:53 PM EDT
Terminated No phase listed Observational

Prevalence of Pathogens in Cerebrospinal Fluid Obtained From Emergency Department Patients

NCT02207647
View directory record Official record
Conditions
Meningoencephalitis, Other Syndromes Requiring Lumbar Puncture in Emergency Department
Interventions
no intervention
Other
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
3 Months and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 11, 2026, 5:53 PM EDT
Completed Phase 2Phase 3 Interventional

Maraviroc and NeuroAIDS Pathogenesis

NCT02159027
View directory record Official record
Conditions
AIDS Dementia Complex
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 11, 2026, 5:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Study Freeze and Transport Immune Cells

NCT00138268
View directory record Official record
Conditions
Diphtheria, Hepatitis B, Pertussis, Poliomyelitis, Tetanus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 11, 2026, 5:53 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine

NCT02466750
View directory record Official record
Conditions
Western Equine Encephalitis
Interventions
Western Equine Encephalitis (WEE) Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 11, 2026, 5:53 PM EDT
Completed No phase listed Observational

Central Nervous System Disease in HIV-infected Children on HAART

NCT00110331
View directory record Official record
Conditions
HIV Infections, Central Nervous System Diseases
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 11, 2026, 5:53 PM EDT